Pharmaceutical Technology1mon
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China. For a complete picture of CD19/CD22 ...
Pharmaceutical Technology1mon
CD19/CD22 CAR-T by Shanghai Unicar-Therapy Bio-Medicine Technology for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China. For a complete picture of CD19/CD22 ...